Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Multiple Myeloma
Multiple Myeloma
EHA 2023: Janssen’s talquetamab shows promise in multiple myeloma
Clinical Trials Arena
Tue, 06/13/23 - 10:39 am
talquetamab
JNJ
Multiple Myeloma
J&J sees trial data supporting earlier CAR-T use in multiple myeloma
BioPharma Dive
Mon, 06/5/23 - 10:12 am
ASCO 2023
JNJ
Legend Biotech
Carvykti
CAR-T
Multiple Myeloma
After FDA's delayed hold for multiple myeloma drug, Molecular Templates is back in action
Fierce Biotech
Thu, 06/1/23 - 06:38 pm
Molecular Templates
clinical trials
MT-0169
FDA
Multiple Myeloma
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
Fierce Pharma
Wed, 04/19/23 - 11:24 am
CAR-T
Bristol Myers Squibb
JNJ
Legend Biotech
AACR
Multiple Myeloma
Carvykti
Abecma
Caribou gets FDA fast track for allogeneic CAR-T
Biopharma Reporter
Tue, 04/11/23 - 10:02 am
Caribou Biosciences
FDA
Multiple Myeloma
CAR-T
CB-011
FDA places partial hold on Molecular Templates’ Phase I trial
Clinical Trials Arena
Mon, 04/10/23 - 11:35 am
Molecular Templates
MT-0169
Multiple Myeloma
clinical trials
This Cancer Drug Candidate Could Be a Hit for Pfizer
Motley Fool
Sun, 03/26/23 - 11:19 pm
Pfizer
elranatamab
Multiple Myeloma
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Fierce Pharma
Sun, 02/12/23 - 07:46 pm
Bristol Myers Squibb
Abecma
CAR-T
Multiple Myeloma
J&J, Legend’s cancer cell therapy has early success in key clinical trial
BioPharma Dive
Mon, 01/30/23 - 10:27 am
JNJ
Legend Biotech
Carvykti
Multiple Myeloma
clinical trials
cell therapy
Sales of J&J, Legend cell therapy plateau amid production challenges
BioPharma Dive
Wed, 01/25/23 - 10:57 pm
JNJ
Legend Biotech
gene therapy
Carvykti
Multiple Myeloma
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
Fierce Pharma
Mon, 12/12/22 - 10:59 pm
Bristol Myers Squibb
ASH 2022
Abecma
clinical trials
Multiple Myeloma
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
Mon, 12/12/22 - 10:56 pm
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets
Fierce Biotech
Mon, 12/12/22 - 10:33 am
ASH 2022
Gracell
CAR-T
Multiple Myeloma
Bristol Myers Squibb
Pfizer
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Fierce Biotech
Fri, 12/9/22 - 10:37 am
Gilead Sciences
Kite Pharma
Arcellx
clinical trials
Multiple Myeloma
cell therapy
JNJ
Legend Biotech
FDA looks to pull approval for Oncopeptides' troubled multiple myeloma drug Pepaxto
Fierce Pharma
Thu, 12/8/22 - 10:01 am
Oncopeptides
Multiple Myeloma
Pepaxto
FDA
GSK to pull blood cancer drug from US market after study failure
BioPharma Dive
Tue, 11/22/22 - 11:08 am
GSK
blood cancer
Blenrep
clinical trials
Multiple Myeloma
Time for GSK to stop dreaming about Blenrep
EP Vantage
Mon, 11/7/22 - 10:53 am
GSK
BCMA
Blenrep
clinical trials
Multiple Myeloma
J&J nabs FDA okay for BCMA bispecific Tecvayli
Pharmaphorum
Wed, 10/26/22 - 07:00 pm
JNJ
Multiple Myeloma
Tecvayli
FDA
FDA advisory committee issues back to back negative votes on two cancer drugs
MedCity News
Mon, 09/26/22 - 10:31 am
FDA
Spectrum Pharmaceuticals
Oncopeptides
clinical trials
poziotinib
Pepaxto
Multiple Myeloma
Despite being approved in Europe, Oncopeptides' Pepaxto will remain sidelined in the US
Fierce Pharma
Sun, 09/25/22 - 02:00 pm
FDA
Oncopeptides
Multiple Myeloma
Pepaxto
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »